Clinical Relevancy Statement {#section1-0148607113517266}
============================

Malnutrition is common in maintenance hemodialysis (MHD) patients and adversely affects their prognosis. Most patients on dialysis have a lower than normal dietary energy and protein intake. Renal-specific oral nutrition supplements (RS-ONS) are required to achieve intake recommendations. The present study clearly indicates that long-term RS-ONS improves the nutrition status of MHD patients with malnutrition.

Introduction {#section2-0148607113517266}
============

Malnutrition is common in patients with chronic kidney disease (CKD) and adversely affects their prognosis.^[@bibr1-0148607113517266][@bibr2-0148607113517266]-[@bibr3-0148607113517266]^

Some patients on dialysis have a lower than normal dietary energy intake (DEI) and dietary protein intake (DPI), and oral nutrition supplements (ONS) are required to achieve intake recommendations.^[@bibr4-0148607113517266]^ Clinical guidelines and literature reviews support enteral nutrition (EN) in patients with renal failure who were diagnosed with malnutrition,^[@bibr5-0148607113517266]^ but there is no consensus on the type, time of initiation, or duration of use. In addition, the benefit of renal-specific ONS (RS-ONS) support in patients without clinical evidence of malnutrition is still unclear.

There are limited ONS clinical trials for dialysis patients.^[@bibr6-0148607113517266][@bibr7-0148607113517266][@bibr8-0148607113517266][@bibr9-0148607113517266][@bibr10-0148607113517266][@bibr11-0148607113517266][@bibr12-0148607113517266][@bibr13-0148607113517266]-[@bibr14-0148607113517266]^ In most of these studies, enteral therapy was associated with improved nutrition status. The aim of this study was to evaluate the nutrition effects of RS-ONS on various outcomes in maintenance hemodialysis (MHD) patients. Based on the hypothesis that daily RS-ONS would prevent or reduce further deterioration of nutrition status of these patients, the present study was designed to compare the effects of RS-ONS and a standard recommended nutrition regime on biochemical and nutrition markers in malnourished patients with CKD on MHD.

Materials and Methods {#section3-0148607113517266}
=====================

Study Population {#section4-0148607113517266}
----------------

Among 286 MHD patients, 62 who were diagnosed as malnourished (serum albumin concentration \<4 g/dL and/or a loss of ≥5% dry weight \[DW\] over the past 3 months) were followed up for 6 months between January and July 2011. Exclusion criteria were as follows: acute infection; chronic inflammatory disease of unknown origin; recent surgery within 3 months or during follow-up; hospitalization, major cardiovascular event, or death during follow-up; nephrotic syndrome; malignancy history; and chronic liver disease.

All inpatients were recommended to use ONS. Nutrition data of patients who agreed to use ONS (n = 32; RS-ONS study group) and those who chose to increase their dietary intake instead (n = 30; control \[CON\] group) were analyzed ([Figure 1](#fig1-0148607113517266){ref-type="fig"}). Twenty-nine patients in each group completed the study. Demographic data were obtained from patient files.

![Study flowchart. RS-ONS, renal-specific oral nutrition supplement.](10.1177_0148607113517266-fig1){#fig1-0148607113517266}

Each serving (200 mL) of RS-ONS preparation (Nutrena; Abbott Nutrition, Zwolle, Holland) contained 400 kcal, 14 g protein, 41.3 g carbohydrate, and 19.2 g fat and had lower concentrations of sodium, potassium, and phosphorus than standard ONS. In the RS-ONS group, 24 patients took 2 daily servings of RS-ONS, whereas 5 patients took 3 daily servings for 6 months. At each dialysis session, RS-ONS consumption and compliance were recorded. A snack providing approximately 300 kcal, 14 g protein, 55 g carbohydrate, and 10 g fat was served to patients during the sessions. Each patient consulted monthly with a dietitian to achieve the target calorie intake of 35 kcal/kg/d.

Written informed consent was obtained from each subject following a detailed explanation of the protocol of the study conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by Baskent University Institutional Review Board (project no. KA11/253).

Anthropometric Measurements {#section5-0148607113517266}
---------------------------

DW and intradialytic weight gain (IDWG) were measured at every MHD session, and monthly average for each patient was recorded. Body mass index (BMI) was calculated at the beginning and end of follow-up period. Triceps skinfold thickness (TSFT)^[@bibr15-0148607113517266]^ was measured from the arm without an arteriovenous fistula and at half-distance between the acromion and the olecranon with a Harpenden caliper (Holtain, Chymycin, UK). Anthropometric and bioelectrical impedance analysis (BIA)^[@bibr16-0148607113517266]^ measurements were performed within 30 minutes after dialysis. Body composition (fat mass \[FM\], fat-free mass \[FFM\], muscle mass \[MM\], and bone mass \[BM\]) was measured using the Tanita BC-420MA Body Composition Analyzer (Tanita, Tokyo, Japan). For the BIA measurements, the subject stood upright with bare feet on the analyzer footpads. The impedance between the feet was measured while an alternating current (50 kHz and \~200 µA) passed through the lower body. FM, FFM, MM, and BM were computed with this impedance value.

Clinical and Biochemical Measurements {#section6-0148607113517266}
-------------------------------------

Predialysis serum concentrations of hemoglobin; creatinine; intact parathyroid hormone; total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol; triglyceride; serum albumin; C reactive protein (CRP); and transferrin saturation levels were assessed and mean erythropoietin dose received was recorded monthly. Each patient's malnutrition and inflammation score^[@bibr17-0148607113517266]^ (MIS), which was created using the 7 components of the conventional Subjective Global Assessment (SGA) and combined with 3 new elements---body mass index (BMI), serum albumin, and total iron-binding capacity (TIBC) and normalized protein catabolic rate^[@bibr18-0148607113517266]^ (nPCR)---were calculated at baseline and at the end of the follow-up.

Statistical Analysis {#section7-0148607113517266}
--------------------

Statistical Package for Social Sciences (version 14.0; SPSS, Inc, an IBM Company, Chicago, IL) was used. The sample size of the study was based on the MHD patients (n = 286) in our center. Data were submitted to a frequency distribution analysis by the Kolmogorov-Smirnov test. Values displaying normal distribution were expressed as mean (standard deviation \[SD\]), and values with skewed distribution were expressed as median (interquartile range \[IQR\]). No method was defined for missing data. Normally distributed numeric variables were analyzed by independent samples *t* or 1-way analysis of variance (ANOVA) (post hoc Tukey) tests according to distribution normality. Skew distributed numeric variables were compared using Mann-Whitney *U* and Kruskal-Wallis tests according to distribution normality. Related data were compared with paired samples *t* or Wilcoxon tests. Categorical data were compared by χ^2^ test, and *P* \< .05 was considered statistically significant.

Results {#section8-0148607113517266}
=======

Baseline Characteristics {#section9-0148607113517266}
------------------------

Mean (SD) age in the RS-ONS group was 62.0 (11.3) years (55.2% female) in the RS-ONS group and 57.2 (12.3) years (31% female) in the CON group. No significant differences were found in age, sex, duration of MHD, basal urea reduction ratio (URR), MIS, and BMI ([Table 1](#table1-0148607113517266){ref-type="table"}).

###### 

Demographical and Clinical Characteristics of All Subjects at Baseline.

  Characteristic                                                          RS-ONS Group (n = 29)   CON Group (n = 29)   *P* Value
  ----------------------------------------------------------------------- ----------------------- -------------------- -----------
  Age, mean (SD), y                                                       62.0 (11.3)             57.2 (12.3)          .130
  Male sex, No. (%)                                                       13 (44.8)               20 (69)              .063
  Duration of HD, mean (SD), y                                            6.5 (4.9)               9.4 (8.7)            .127
  Etiology of CKD, No. (%)                                                                                             .986
   Diabetes mellitus                                                      5 (17.2)                4 (13.8)             
   Hypertension                                                           9 (31.0)                8 (27.5)             
   Glomerulonephropathy                                                   4 (13.8)                6 (20.6)             
   Unknown reason                                                         2 (6.9)                 1 (3.4)              
   Other reasons^[a](#table-fn2-0148607113517266){ref-type="table-fn"}^   9 (31.0)                10 (34.4)            
  URR, mean (SD)                                                          68.3 (6.7)              68.2 (6.4)           .968
  MIS, mean (SD), points                                                  8.3 (2.8)               7.3 (2.7)            .169
  BMI, mean (SD), kg/m^2^                                                 22.7 (4.0)              23.8 (4.7)           .355

BMI, body mass index; CKD, chronic kidney disease; CON, control; HD, hemodialysis; MIS, malnutrition and inflammation score; RS-ONS, renal-specific oral nutrition supplementation; SD, standard deviation; URR, urea reduction ratio.

Includes nephrolithiasis, polycystic kidney disease, renal artery stenosis, systemic lupus erythematosus, tubulointerstitial nephritis, vesicoureteral reflux, familial Mediterranean fever, and Fabry disease.

Biochemical Findings {#section10-0148607113517266}
--------------------

Mean (SD) levels of serum albumin were significantly increased in the RS-ONS group from 3.5 (0.3) g/dL at baseline to 3.7 (0.2) g/dL at 6 months (*P* = .028) but not changed in the CON group. Serum albumin levels at 6 months were significantly higher in the RS-ONS group compared with the CON group (3.7 \[0.2\] vs 3.5 \[0.3\] g/dL; *P* = .012) ([Table 2](#table2-0148607113517266){ref-type="table"}).

###### 

Laboratory Findings, Anthropometric Indicators, MIS, nPCR, and Erythropoietin Requirement in RS-ONS and CON Groups: Baseline and 6-Month Comparison Between and Within Groups.

                                   RS-ONS Group      CON Group                                                                                         
  -------------------------------- ----------------- ----------------- ------------------------------------------------------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hemoglobin, g/dL                 11.1 (1.2)        11.3 (1.2)        10.7 (1.7)                                                    10.7 (1.5)        ---
  Creatinine, mg/dL                7.5 (2.0)         7.5 (1.8)         8.8 (2.3)                                                     8.4 (2.5)         .031^[a](#table-fn4-0148607113517266){ref-type="table-fn"}^
  Intact PTH, pg/mL                652.1 (688.1)     546.0 (519.3)     770.6 (738.8)                                                 694.3 (638.6)     ---
  Total cholesterol, mg/dL         160.1 (34.9)      164.2 (39.0)      149.9 (41.9)                                                  148.1 (34.2)      ---
  LDL-cholesterol, mg/dL           89.3 (30.1)       93.4 (30.1)       76.9 (24.0)                                                   76.1 (28.4)       .028^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^
  HDL-cholesterol, mg/dL           38.9 (15.4)       39.6 (9.5)        34.8 (10.1)                                                   37.1 (10.6)       ---
  Triglyceride, mg/dL              125.0 (64.0)      119.6 (59.7)      120.1 (72.9)                                                  112.2 (50.6)      ---
  Serum albumin, g/dL              3.5 (0.3)         3.7 (0.2)         3.4 (0.3)                                                     3.5 (0.3)         .012,^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^ .028^[c](#table-fn6-0148607113517266){ref-type="table-fn"}^
  CRP, g/dL                        6.0 (21.6)        7.4 (12.0)        6.1 (27.5)                                                    11.0 (22.0)       ---
  Lymphocyte, mm^3^                1410 (625)        1330 (755)        1500 (1000)                                                   1670 (940)        ---
  White blood cells, mm^3^         7219.7 (2253.2)   6724.8 (2427.6)   7014.5 (1809.1)                                               6568.6 (2082.0)   ---
  Transferrin saturation, %        47.82 (65.1)      54.4 (34.4)       36.8 (26.7)                                                   55.6 (48.1)       .049^[d](#table-fn7-0148607113517266){ref-type="table-fn"}^
  URR                              68.3 (6.7)        68.2 (6.4)        70.7 (6.6)                                                    69.7 (5.6)        ---
  Dry weight, kg                   58.1 (10.3)       59.0 (10.4)       65.5 (15.2)                                                   63.9 (15.0)       .034,^[a](#table-fn4-0148607113517266){ref-type="table-fn"}^ \<.001^[c](#table-fn6-0148607113517266){ref-type="table-fn"},[d](#table-fn7-0148607113517266){ref-type="table-fn"}^
  Intradialytic weight gain, kg    2.9 (0.6)         3.1 (0.6)         3.0 (0.9)                                                     3.0 (0.8)         ---
  BMI, kg/m^2^                     22.7 (4.0)        22.9 (3.7)        23.8 (4.7)                                                    23.0 (4.5)        \<.001^[d](#table-fn7-0148607113517266){ref-type="table-fn"}^
  Triceps skinfold thickness, cm   10.5 (5.0)        11.9 (5.0)        12.6 (5.4)                                                    11.3 (5.5)        \<.001^[c](#table-fn6-0148607113517266){ref-type="table-fn"},[d](#table-fn7-0148607113517266){ref-type="table-fn"}^
  Fat mass, kg                     14.8 (8.8)        15.0 (8.9)        14.7 (10.1)                                                   14.6 (9.8)        ---
  Fat-free mass, kg                43.5 (6.8)        44.3 (6.9)        51.0 (9.1)                                                    49.0 (9.2)        \<.001,^[a](#table-fn4-0148607113517266){ref-type="table-fn"},[d](#table-fn7-0148607113517266){ref-type="table-fn"}^ .030^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^
  Muscle mass, kg                  41.3 (6.5)        42.0 (6.4)        48.4 (8.6)                                                    46.5 (8.8)        \<.001,^[a](#table-fn4-0148607113517266){ref-type="table-fn"},[d](#table-fn7-0148607113517266){ref-type="table-fn"}^ .028^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^
  Bone mass, kg                    2.2 (0.3)         2.3 (0.3)         2.6 (0.4)                                                     2.5 (0.4)         \<.001,^[a](#table-fn4-0148607113517266){ref-type="table-fn"},[d](#table-fn7-0148607113517266){ref-type="table-fn"}^ .037^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^
  MIS, score                       8.3 (2.8)         8.2 (3.0)         7.3 (2.7)                                                     8.8 (3.4)         \<.006^[d](#table-fn7-0148607113517266){ref-type="table-fn"}^
  nPCR, g/kg/d                     0.91 (0.17)       0.93 (0.17)       0.94 (0.18)                                                   0.89 (0.17)       ---
  rHuEPO dose change, %            --14.77 (35)      1.38 (24.14)      .012^[b](#table-fn5-0148607113517266){ref-type="table-fn"}^                     

Values are expressed as mean (SD). CON, control; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; URR, urea reduction ratio; BMI, body mass index; MIS, malnutrition and inflammation score; nPCR, normalized protein catabolic rate; rHuEPO, recombinant human erythropoietin; IQR, interquartile range; RS-ONS, renal-specific oral nutrition supplementation; ---, p \>.05.

*P* values for baseline comparison between groups.

*P* values for 6-month comparison between groups.

*P* values for baseline vs 6-month comparison in the RS-ONS group.

*P* values for baseline vs 6-month comparison in the CON group.

Following RS-ONS initiation, there was a significant increase in serum albumin from months 1--6 (*P* = .012) ([Figure 2](#fig2-0148607113517266){ref-type="fig"}). Although RS-ONS and CON groups were similar in terms of the percentage of patients with serum albumin levels \<3.5 g/dL at baseline (48.3% vs 58.6%, respectively; *P* = .430), the RS-ONS group had significantly fewer such patients at month 6 compared with the CON group (17.2% vs 48.3%; *P* = .012) ([Figure 3](#fig3-0148607113517266){ref-type="fig"}).

![Mean serum albumin concentration (g/dL) in oral nutrition supplementation (ONS) and control groups during the study period.](10.1177_0148607113517266-fig2){#fig2-0148607113517266}

![Percentage of patients with serum albumin level of \<3.5 g/dL in oral nutrition supplementation (ONS) and control groups at baseline and month 6 of the study.](10.1177_0148607113517266-fig3){#fig3-0148607113517266}

Considering lipid only, mean (SD) serum LDL-cholesterol levels were higher in the RS-ONS group (93.4 \[30.1\] mg/dL) at the end of the study (*P* = .028) but still within normal limits (\<160.0 mg/dL). The CON group had a significant accretion in mean (SD) transferrin saturation ratios from 36.8% (26.7%) at baseline to 55.6% (48.1%) at month 6 (*P* = .049). Dialysis adequacy did not differ between groups at any time (*P* = .968 and *P* = .567, respectively) ([Table 2](#table2-0148607113517266){ref-type="table"}).

Anthropometrical Measurements {#section11-0148607113517266}
-----------------------------

At baseline, DW in the RS-ONS group was significantly lower than that in the CON group (*P* = .034), but at 6 months, a significant increase in the RS-ONS but a decrease in the CON group was observed (*P* \< .001 for each) ([Table 2](#table2-0148607113517266){ref-type="table"}).

BMI of the 2 groups was similar at baseline (*P* = .355); the CON group exhibited a significant decrease from baseline to month 6 (*P* \< .001), while BMI remained stable in the RS-ONS group. The RS-ONS group's TSFT significantly increased at the end of the study, but the CON group had a significant decline from 12.6 (5.4) to 11.3 (5.5) cm (*P* \< .001 for both). At baseline, the CON group had significantly higher levels of FFM, MM, and BM. During the 6 months of the study, FFM, MM, and BM remained stable in the RS-ONS group while the CON group experienced significant declines in all (*P* \< .001 for each) ([Table 2](#table2-0148607113517266){ref-type="table"}).

Percent changes from baseline values in DW, BMI, and BIA measurements, including FFM, MM, and BM, were negative in the CON group (*P* \< .001 for each) ([Figure 4](#fig4-0148607113517266){ref-type="fig"}).

![Percent change in dry weight (DW), body mass index (BMI), fat-free mass (FFM), muscle mass (MM), and bone mass (BM) at the end of the study oral nutrition supplementation (ONS) and control groups.](10.1177_0148607113517266-fig4){#fig4-0148607113517266}

Malnutrition and inflammation scores were similar in both groups at baseline (*P* = .682) but increased significantly in the CON group at month 6 (*P* = .006) while remaining stable in the RS-ONS group. nPCR was similar between the 2 groups at baseline (*P* = .487). Although there were numerical decreases in the nPCR level during the study period in the CON group, the change did not reach statistical significance (*P* = .097). Although hemoglobin levels of both groups did not show statistically significant changes during the study, the CON group required significantly higher erythropoietin doses compared with the RS-ONS group (*P* = .012) to maintain steady hemoglobin levels ([Table 2](#table2-0148607113517266){ref-type="table"}).

Adverse Events {#section12-0148607113517266}
--------------

The most frequent adverse events in the RS-ONS group were digestive symptoms, mainly diarrhea, nausea, and abdominal distention, as observed in 5 patients. They were recommended to decrease the dose of RS-ONS to 1 can/d, and in 3 cases, RS-ONS was discontinued. In addition, 1 patient in the CON group died of an acute cerebrovascular event.

Discussion {#section13-0148607113517266}
==========

Our findings revealed that RS-ONS significantly improved nutrition parameters in malnourished patients with CKD, similar to a previous prospective study.^[@bibr11-0148607113517266]^ Notably, several clinically undiagnosed nutrition parameters deteriorated in patients who declined nutrition supplementation.

Hypoalbuminemia is most likely the strongest predictor of mortality among MHD patients.^[@bibr19-0148607113517266]^ Seven randomized and nonrandomized trials with ONS reported significant improvements in serum albumin levels.^[@bibr6-0148607113517266][@bibr7-0148607113517266][@bibr8-0148607113517266][@bibr9-0148607113517266]-[@bibr10-0148607113517266],[@bibr12-0148607113517266],[@bibr14-0148607113517266]^ In our study population, a significant increase in serum albumin was observed only in the RS-ONS group and a significant reduction in the percentage of patients with serum albumin \<3.5 g/dL at the end of the follow-up period. Therefore, it seems reasonable to consider the significant improvement in serum albumin as well as nutrition status in patients receiving RS-ONS to result in lower inflammatory status.

Considering the suggested relation of anthropometrics,^[@bibr19-0148607113517266][@bibr20-0148607113517266]-[@bibr21-0148607113517266]^ it is worth noting that a significant increase in DW, BMI, and TSFT was evident in the RS-ONS group, while the CON group showed a significant decline.

BIA is an easy-to-implement and a useful nutrition assessment tool to monitor health status, determine long-term follow-up, and detect early losses of lean body mass in MHD patients.^[@bibr6-0148607113517266]^ In this study, both groups were similar in terms of demographic and clinical data, and baseline and 6-month BIA values were higher in the CON group. The possible explanation of this result may be that patients in the CON group might have been feeling better at the initiation of the study, with better appetite and nutrition intake. But at the end of the study, while BIA values of the CON group significantly decreased, an increase of 1%−2% was observed in the experimental group.

Exploring the relationship between measures of body composition and anemia, we observed a 14.8% decrease in EPO dose for patients receiving RS-ONS.

The present study clearly indicates that RS-ONS improves the nutrition status of patients in MHD patients with malnutrition. Albeit no relationship was determined between body composition and markers of inflammation, improvement of MIS and EPO requirement in the RS-ONS group seems notable.

Previously, our clinical approach was to advise an increase in nutrition intake when minor signs of malnutrition were detected in our patients. However, the present findings suggest that earlier introduction of RS-ONS improves nutrition status.

One of the limitations of this study is the higher baseline and 6-month BIA values in the CON group. The total daily protein/calorie intake was not assessed, and we did not use a more sensitive reference method to estimate body composition (like dual-energy x-ray absorptiometry).

Conclusion {#section14-0148607113517266}
==========

In conclusion, our findings indicate that consuming RS-ONS at home improves the nutrition and inflammatory status of patients with CKD, which suggests development of a rational approach to detect minor signs of malnutrition early as well as a reasonable treatment strategy.
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